Drugs / D3S-001
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07093398 | Jul → Nov 2025 | — | D3 Bio (Wuxi) Co., Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05886920 | Jul 2023 → Aug 2028 expected | — | D3 Bio (Wuxi) Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05410145 | Aug 2022 → Apr 2027 expected | acute myeloid leukemia, KRAS gene mutation | D3 Bio (Wuxi) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D3S-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05410145 ↗ |
| Action | Inhibit | “D3S-001 is a next-generation KRAS-G12C inhibitor (G12Ci)” PMID 40301557 ↗ Apr 2025 |
| Modality | Small molecule | — CHEMBL5314913 ↗ |
| Route | Oral | “D3S-001 will be taken daily by oral administration in 21-day treatment cycles.” NCT05410145 ↗ |
| Target | KRAS | “D3S-001 is a next-generation KRAS-G12C inhibitor (G12Ci)” PMID 40301557 ↗ Apr 2025 |